1 citations
,
July 2024 in “JAAD International” Low-dose oral minoxidil is effective for alopecia even with other medications.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
14 citations
,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
1 citations
,
May 2026 in “Journal of Dermatological Treatment” JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.
4 citations
,
January 2022 in “Drug design, development and therapy” Intramuscular corticosteroids are effective and safe for severe alopecia areata, with most patients regrowing hair, but nearly half may relapse.
December 2025 in “Journal of Dermatological Treatment” GT20029 helps regrow hair in men with hair loss and is well-tolerated.
11 citations
,
October 2016 in “Pediatric dermatology” Stopping the use of fluocinolone oil containing balsam fragrance improved hair regrowth in children allergic to it.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
February 2026 in “Inflammopharmacology” Pistacia atlantica leaf ointment effectively heals wounds like phenytoin, with added antibacterial and anti-inflammatory benefits.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
October 2007 in “Inpharma Weekly”
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
Neonatal allopregnanolone and stress affect behavior differently in adolescence and adulthood.
April 2021 in “Research Square (Research Square)” The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” October 2023 in “IP Indian Journal of Clinical and Experimental Dermatology” The luliconazole shampoo effectively reduces symptoms of seborrheic dermatitis and is well-tolerated.
13 citations
,
June 2010 in “Journal of dermatological treatment” Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
March 2021 in “Research Square (Research Square)” Strontium ranelate helps cartilage growth by blocking a specific cell pathway.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
April 2025 in “Egyptian journal of Immunology” Calprotectin levels are higher in alopecia areata patients, indicating systemic inflammation.
May 2025 in “International Ayurvedic Medical Journal” Ayurvedic Shamana therapy effectively treats alopecia areata with minimal side effects.
21 citations
,
April 2011 in “Epilepsia” The drug combination significantly reduced epileptic drop attacks in patients.
9 citations
,
October 1947 in “The Lancet” 1 citations
,
November 1947 in “The Lancet”